| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $592,389 | 3 | 100 |
| Lingamneni Anila | EVP, Chief Technology Officer | 0 | $0 | 2 | $199,350 | $-199,350 |
| Strong Stewart W | President, Global Hospital | 0 | $0 | 1 | $393,039 | $-393,039 |
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at Haemonetics Corporation have bought $0 and sold $592,389 worth of Haemonetics Corporation stock.
On average, over the past 5 years, insiders at Haemonetics Corporation have bought $323,720 and sold $3.51M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,000 shares for transaction amount of $323,720 was made by ABERNATHY ROBERT E (director) on 2020‑08‑11.
| 2024-07-26 | Sale | Strong Stewart W | President, Global Hospital | 4,312 0.0085% | $91.15 | $393,039 | -19.48% | |
| 2024-07-12 | Sale | Lingamneni Anila | EVP, Chief Technology Officer | 79 0.0002% | $90.00 | $7,110 | -18.34% | |
| 2024-07-11 | Sale | Lingamneni Anila | EVP, Chief Technology Officer | 2,136 0.0045% | $90.00 | $192,240 | -17.33% | |
| 2024-05-29 | Sale | Basil Michelle L | EVP and General Counsel | 12,990 0.0257% | $88.08 | $1.14M | -13.85% | |
| 2024-05-29 | Sale | Strong Stewart W | President, Global Hospital | 8,857 0.0174% | $87.53 | $775,253 | -13.85% | |
| 2024-05-20 | Sale | Basil Michelle L | EVP and General Counsel | 1,604 0.0032% | $95.08 | $152,508 | -20.68% | |
| 2024-05-20 | Sale | Llorens Josep | EVP, Global Manufacturing | 987 0.0019% | $95.08 | $93,844 | -20.68% | |
| 2024-05-20 | Sale | Strong Stewart W | President, Global Hospital | 686 0.0013% | $95.11 | $65,245 | -20.68% | |
| 2024-05-17 | Sale | Basil Michelle L | EVP and General Counsel | 1,073 0.0021% | $95.00 | $101,935 | -21.05% | |
| 2024-05-17 | Sale | Llorens Josep | EVP, Global Manufacturing | 822 0.0016% | $94.82 | $77,942 | -21.05% | |
| 2024-05-16 | Sale | Basil Michelle L | EVP and General Counsel | 985 0.002% | $96.14 | $94,698 | -20.26% | |
| 2024-05-16 | Sale | Llorens Josep | EVP, Global Manufacturing | 770 0.0015% | $96.14 | $74,028 | -20.26% | |
| 2024-05-16 | Sale | Strong Stewart W | President, Global Hospital | 733 0.0015% | $96.04 | $70,397 | -20.26% | |
| 2024-05-06 | Sale | Lingamneni Anila | EVP, Chief Technology Officer | 2,305 0.0045% | $95.00 | $218,975 | -19.99% | |
| 2023-09-12 | Sale | Strong Stewart W | President, Global Hospital | 228 0.0005% | $90.65 | $20,668 | -5.54% | |
| 2023-09-11 | Sale | Lingamneni Anila | EVP, Chief Technology Officer | 2,305 0.0045% | $90.00 | $207,450 | -6.30% | |
| 2023-09-05 | Sale | Dockendorff Charles J | director | 10,215 0.0202% | $87.68 | $895,651 | -2.36% | |
| 2023-07-18 | Sale | Llorens Josep | EVP, Global Manufacturing | 4,928 0.0095% | $90.00 | $443,520 | -6.20% | |
| 2023-06-07 | Sale | Strong Stewart W | President, Global Hospital | 2,538 0.005% | $88.04 | $223,446 | -2.39% | |
| 2023-05-30 | Sale | Lingamneni Anila | EVP, Chief Technology Officer | 2,304 0.0045% | $83.33 | $191,992 | +3.00% |
| Lingamneni Anila | EVP, Chief Technology Officer | 21331 0.0444% | $1.49M | 0 | 9 | |
| Strong Stewart W | President, Global Hospital | 18196 0.0379% | $1.27M | 0 | 9 | |
| Simon, Christopher | President & CEO | 213724 0.4449% | $14.97M | 1 | 21 | +13.41% |
| CONCANNON BRIAN | President & CEO | 147040 0.3061% | $10.3M | 8 | 57 | +8.69% |
| GELBMAN RONALD G | director | 48384 0.1007% | $3.39M | 1 | 16 | +4.67% |
| LINDOP CHRISTOPHER J | CFO & EVP Business Development | 45350 0.0944% | $3.18M | 12 | 15 | +4.66% |
| ALLEN PETER M | President, Global Plasma | 34102 0.071% | $2.39M | 20 | 22 | +7.23% |
| MEELIA RICHARD J | director | 32050 0.0667% | $2.25M | 0 | 4 | |
| Basil Michelle L | EVP and General Counsel | 31257 0.0651% | $2.19M | 0 | 31 | |
| White Jonathan | Chief Science and Technology | 30507 0.0635% | $2.14M | 7 | 5 | +3.73% |
| Burke William P. Mr. | EVP, Chief Financial Officer | 30291 0.0631% | $2.12M | 0 | 26 | |
| Llorens Josep | EVP, Global Manufacturing | 21310 0.0444% | $1.49M | 0 | 14 | |
| FOOTE SUSAN BARTLETT | director | 20740 0.0432% | $1.45M | 1 | 9 | <0.0001% |
| HANLON SUSAN M | VP Finance | 20464 0.0426% | $1.43M | 18 | 20 | +5.11% |
| Jesse Sandra | EVP and Chief Legal Officer | 20096 0.0418% | $1.41M | 3 | 2 | +5.46% |
| MERRIMAN RONALD | director | 17807 0.0371% | $1.25M | 1 | 9 | <0.0001% |
| FORISH JOSEPH J | VP, Human Resources | 17279 0.036% | $1.21M | 9 | 10 | +4.98% |
| Davies Kent J | Chief Operating Officer | 16891 0.0352% | $1.18M | 0 | 2 | |
| KROLL MARK W | 16231 0.0338% | $1.14M | 0 | 10 | ||
| Burns Brian R | EVP, Global QA/RA | 16235 0.0338% | $1.14M | 0 | 1 | |
| EBBELING ROBERT B | Vice President, Operations | 15849 0.033% | $1.11M | 9 | 4 | +6.35% |
| GRANADILLO PEDRO P | director | 15335 0.0319% | $1.07M | 4 | 13 | +2.48% |
| Ryding Neil Mr. | EVP, Global Manufacturing | 15226 0.0317% | $1.07M | 0 | 4 | |
| Miller Laurie A. | SVP, Human Resources | 12697 0.0264% | $889,551.82 | 0 | 6 | |
| Granville William | VP, Manufacturing | 12188 0.0254% | $853,891.28 | 1 | 0 | +4.75% |
| ABERNATHY ROBERT E | director | 12048 0.0251% | $844,082.88 | 1 | 0 | +18.77% |
| Selman Byron | President, Global Markets | 12010 0.025% | $841,420.60 | 0 | 2 | |
| LOPEZ ALICIA R | VP, Corporate Affairs | 11017 0.0229% | $771,851.02 | 13 | 24 | +4.9% |
| Kelly Michael P | President, Global Markets | 10987 0.0229% | $769,749.22 | 0 | 11 | |
| BEST LAWRENCE C | director | 10001 0.0208% | $700,670.06 | 1 | 7 | +0.57% |
| NUTTER BRAD | Chairman of the Board | 9387 0.0195% | $657,653.22 | 1 | 11 | +26.67% |
| Nighan Warren JR | VP WW Q&R Affairs | 7908 0.0165% | $554,034.48 | 0 | 2 | |
| Helsel Dave | EVP, Global Manufacturing | 6856 0.0143% | $480,331.36 | 2 | 0 | +2.96% |
| McDaniel Kathleen | EVP Global Human Resources | 5013 0.0104% | $351,210.78 | 0 | 1 | |
| Popovsky Mark A | VP, Corporate Medical Director | 4891 0.0102% | $342,663.46 | 7 | 5 | +4.13% |
| Goldstein Dan | VP, Corporate Controller | 4447 0.0093% | $311,556.82 | 0 | 40 | |
| Gordon Mikael | President, Global Markets | 4442 0.0092% | $311,206.52 | 3 | 5 | +6.2% |
| Scanlan Jacqueline | SVP, Global Human Resources | 4216 0.0088% | $295,372.96 | 0 | 24 | |
| Still William Roche | VP & Gen Mrg, Therapeutics Bus | 4193 0.0087% | $293,761.58 | 6 | 2 | +1.45% |
| O'Shaughnessy James | 3781 0.0079% | $264,896.86 | 1 | 0 | +4.75% | |
| Brancazio Phillip John | VP, Global Manufacturing | 3052 0.0064% | $213,823.12 | 3 | 0 | +0.64% |
| SWENSON STEPHEN | VP & General Mgr, Global Plasm | 3024 0.0063% | $211,861.44 | 1 | 2 | +4.75% |
| Pare Anthony | 2523 0.0053% | $176,761.38 | 1 | 2 | +4.75% | |
| SAKURADA YUTAKA | President, Japan & Asia | 2347 0.0049% | $164,430.82 | 2 | 0 | +16.87% |
| Dockendorff Charles J | director | 2226 0.0046% | $155,953.56 | 0 | 2 | |
| RYAN RONALD J | VP and CFO | 2101 0.0044% | $147,196.06 | 5 | 4 | +5.1% |
| BEUCLER MARK | 1989 0.0041% | $139,349.34 | 1 | 0 | +4.75% | |
| Bolorforosh Said | EVP, Chief Technology Officer | 1977 0.0041% | $138,508.62 | 0 | 3 | |
| WILLIAMSON DONNA C E | director | 1300 0.0027% | $91,078.00 | 0 | 4 | |
| Conneely Jan | VP & GM, Arryx, Inc. | 1041 0.0022% | $72,932.46 | 1 | 0 | +4.75% |
| ECKERT ULRICH | President, Europe & Latin Am | 890 0.0019% | $62,353.40 | 2 | 4 | +2.88% |
| Corlin Remi | President, Asia | 884 0.0018% | $61,933.04 | 0 | 2 | |
| Hattori Keiko | President, Haemonetics Japan | 716 0.0015% | $50,162.96 | 1 | 0 | +4.75% |
| RUXIN MICHAEL I | VP Global Software Strategies | 215 0.0004% | $15,062.90 | 1 | 0 | +6.76% |
| Sakai Ryoji | President, Japan | 0 0% | $0 | 0 | 3 | |
| Lawlor Thomas | President, Patient Division | 0 0% | $0 | 0 | 1 |
| Increased Positions | 182 | +53.85% | 7M | +12.15% |
| Decreased Positions | 153 | -45.27% | 9M | -16.15% |
| New Positions | 55 | New | 3M | New |
| Sold Out Positions | 47 | Sold Out | 2M | Sold Out |
| Total Postitions | 367 | +8.58% | 55M | -4% |
| Blackrock, Inc. | $405,905.00 | 12.71% | 6.36M | +197,260 | +3.2% | 2025-03-31 |
| Vanguard Group Inc | $330,704.00 | 10.36% | 5.18M | +10,119 | +0.2% | 2024-12-31 |
| Neuberger Berman Group Llc | $282,175.00 | 8.84% | 4.42M | +392,240 | +9.74% | 2024-12-31 |
| Capital Research Global Investors | $270,657.00 | 8.48% | 4.24M | -203,699 | -4.58% | 2024-12-31 |
| Wellington Management Group Llp | $251,583.00 | 7.88% | 3.94M | -261,341 | -6.22% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $163,061.00 | 5.11% | 2.55M | -296,823 | -10.41% | 2024-12-31 |
| State Street Corp | $124,315.00 | 3.89% | 1.95M | +58,494 | +3.1% | 2024-12-31 |
| Thrivent Financial For Lutherans | $80,725.00 | 2.53% | 1.26M | +164,111 | +14.92% | 2024-12-31 |
| Geode Capital Management, Llc | $75,410.00 | 2.36% | 1.18M | -12,878 | -1.08% | 2024-12-31 |
| Royce & Associates Lp | $73,636.00 | 2.31% | 1.15M | -57,278 | -4.73% | 2024-12-31 |